CAMP4 Therapeutics Corporation Variable Lease, Cost
CAMP4 Therapeutics Corporation (CAMP) reported Variable Lease, Cost of $361.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-13
- CAMP4 Therapeutics Corporation variable lease, cost for the quarter ending 2026-06-30 was $361.00K, a 1.10% decline year-over-year.
- CAMP4 Therapeutics Corporation variable lease, cost for the quarter ending 2026-03-31 was $370.00K, a 26.28% increase year-over-year.
- CAMP4 Therapeutics Corporation variable lease, cost for the quarter ending 2025-12-31 was $361.00K, a 4.64% increase year-over-year.
- CAMP4 Therapeutics Corporation variable lease, cost for the quarter ending 2025-09-30 was $358.00K, a 4.07% increase year-over-year.
- CAMP4 Therapeutics Corporation variable lease, cost for fiscal 2025 was $1.38M, a 1.10% increase from fiscal 2024.
- CAMP4 Therapeutics Corporation variable lease, cost for fiscal 2024 was $1.36M, a 12.28% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation variable lease, cost for fiscal 2023 was $1.21M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $361.00K 10-Q · filed 2026-08-13 | $731.00K 10-Q · filed 2026-08-13 | $1.09M derived: sum of 3 quarters · filed 2026-08-13 | $1.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $370.00K 10-Q · filed 2026-05-07 | $731.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.09M derived: sum of 3 quarters · filed 2026-05-07 | $1.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $361.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $719.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.08M derived: sum of 3 quarters · filed 2026-08-13 | $1.38M 10-K · filed 2026-03-05 |
| 2025-09-30 | $358.00K 10-Q · filed 2025-11-06 | $723.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.02M 10-Q · filed 2025-11-06 | $1.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $365.00K 10-Q · filed 2026-08-13 | $658.00K 10-Q · filed 2026-08-13 | $1.00M derived: sum of 3 quarters · filed 2026-08-13 | $1.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $293.00K 10-Q · filed 2026-05-07 | $638.00K derived: sum of 2 quarters · filed 2026-05-07 | $982.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.32M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $345.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $689.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.03M derived: sum of 3 quarters · filed 2026-03-05 | $1.36M 10-K · filed 2026-03-05 |
| 2024-09-30 | $344.00K 10-Q · filed 2025-11-06 | $682.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.02M 10-Q · filed 2025-11-06 | $1.37M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $338.00K 10-Q · filed 2025-08-14 | $673.00K 10-Q · filed 2025-08-14 | $1.02M derived: sum of 3 quarters · filed 2025-08-14 | $1.31M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $335.00K 10-Q · filed 2025-05-13 | $686.00K derived: sum of 2 quarters · filed 2025-05-13 | $972.00K derived: sum of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | $351.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $637.00K derived: sum of 2 quarters · filed 2025-03-27 | $1.21M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $286.00K 10-Q · filed 2024-11-21 | $862.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |